Aker BP and Cognite Pioneer Robotics Deployment Offshore to Transform Oil and Gas Industry with Autonomous Mission
Cognitea global industrial AI software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world, has partnered with fully-fledged exploration and production company Aker BP to deploy Spot, the quadruped robotic dog, to pioneer the remote controlled offshore mission on the Skarv installation, 210 kilometers offshore in the North Sea.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005292/en/
Cognite Data Fusion powers Spot, the Boston Dynamics quadruped robot dog, as it completes autonomous mission onboard Aker BP Skarv installation in the North Sea (Photo: Business Wire)
The effort continues to build upon Aker BP and Cognite’s bold digital agenda to transform the industry through digitalization, which will result in improved efficiency, safety, and sustainability offshore. This recent endeavor signals a significant opportunity to transform the oil and gas industry worldwide.
Aker BP is committed to affordable, reliable, sustainable, and modern energy for all, and using robotics is a strong part of this vision. Spot’s work offshore is the next step in his journey as he was issued his official employee number in February at the Aker BP Capital Markets Day. In addition Aker BP has a number of other projects involving drones and additional mobile robots to deliver on their vision of optimized remote operations using Cognite’s data driven technology.
Cognite’s main software product, Cognite Data Fusion (CDF), served as the data infrastructure for the offshore test which collected images, scans, and sensors from robotics systems and then shared the data across Aker BP via a dashboard to make it actionable. Tasks included: autonomous inspection, high-quality data capture, and automatic report generation. These data insights provide onshore operators with telepresence on offshore installations allowing them complete realtime mission planning and help drive crucial activities.
The mobility of Spot offshore, and the communication between Spot, Cognite Data Fusion and Aker BP was both verified and tested. Data from Spot was available and sorted in Cognite Data Fusion in milliseconds, and Spot was remote controlled from a Cognite home office onshore demonstrating how robots and digital twins can have synergies and enhance each other. In addition, data from an operator round was collected to analyze if the sensor-stack on Spot was sufficient to comply with the proposed task.
“We are eager to explore how robotics systems can make offshore operations safer, more efficient, and more sustainable. The Spot offshore visit at the Skarv FPSO is one small step towards Aker BP’s vision to digitalize all our operations from cradle to grave to increase productivity, enhance quality, and improve the safety of our employees,” said Karl Johnny Hersvik, CEO of Aker BP.
“Missions like these demonstrate Spot’s value in difficult environments. Cognite continues to excel in testing and validating Spot’s ability to reduce risk to humans and provide value in the energy industry,” said Michael Perry, Vice President of Business Development at Boston Dynamics.
“This historic pairing of minds and machines working together to solve industry problems demonstrates that data driven decisions can change industry now,” said Dr. John Markus Lervik, CEO of Cognite. “This ability to guide Spot by remote control is a huge step forward for the industry and something we will continue to work closely with our partners on as we continue to innovate and provide data driven solutions.”
Cognite Data Fusion (CDF) is a cloud-based industrial data operations and intelligence platform, and it integrates seamlessly with existing IT and OT applications in the cloud, edge, and on-premise. CDF contextually enriches industrial data, providing an open, unified industrial data model that is easily accessible for humans and applications, enabling better analytical operations and data-driven decisions.
Cognite is a global industrial software-as-a-service (SaaS) company supporting the full-scale digital data driven transformation of heavy-asset industries around the world. Our core product, Cognite Data Fusion (CDF), is an industrial data operations and contextualization platform, putting raw data into real-world industrial context, enabling rapid application & solution creation at scale. CDF powers companies with contextualized OT/IT/ET data to develop solutions that increase safety, sustainability, efficiency, and drive revenue. Visit us at www.cognite.com and follow us on Twitter @CogniteData or at LinkedIn: https://www.linkedin.com/company/cognitedata
About Aker BP
Aker BP is a fully-fledged E&P company with exploration, development and production activities on the Norwegian Continental Shelf (NCS). Measured in production, Aker BP is one of the largest independent oil companies in Europe. Aker BP is the operator of Alvheim, Ivar Aasen, Skarv, Valhall, Hod, Ula and Tambar, partner in the Johan Sverdrup field and has a total of 141 licenses, including non-operated licenses. Aker BP holds no oil or gas assets outside Norway. Visit us at www.akerbp.com or follow us at LinkedIn, Facebook or Instagram.
Global PR Lead
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CET | Press release
Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti
H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CET | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas
Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CET | Press release
Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa
TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit
Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and
Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CET | Press release
Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in
Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CET | Press release
Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom